The incidence of tuberculosis (TB) in Allo-HSCT recipients in a low-incidence country (France) is approximately 60 per 100,000 patient-years, significantly higher than the general population.
The most potent independent risk factor is being born in a high-TB-incidence country (OR = 19.4), emphasizing the role of reactivation of latent TB infection (LTBI).
Extrapulmonary TB is the dominant presentation (82% of cases), often complicating diagnosis and requiring prolonged multi-drug therapy.
Management is hindered by severe adverse drug reactions (25%) and TB-attributable mortality (9%), necessitating rigorous pre-transplant screening protocols.
Background
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.